Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer.
Expert Panel on Radiation Oncology-Prostate; Frank SJ, Arterbery VE, Hsu IC, Abdel-Wahab M, Ciezki JP, Hahn NM, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G. Expert Panel on Radiation Oncology-Prostate, et al. Among authors: ciezki jp. Brachytherapy. 2011 Sep-Oct;10(5):357-62. doi: 10.1016/j.brachy.2011.01.014. Epub 2011 Apr 16. Brachytherapy. 2011. PMID: 21497562 Review.
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.
Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA. Kupelian PA, et al. Among authors: ciezki jp. Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33. doi: 10.1016/s0360-3016(03)00784-3. Int J Radiat Oncol Biol Phys. 2004. PMID: 14697417
A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
Ciezki JP, Klein EA, Angermeier K, Ulchaker J, Chehade N, Altman A, Mahadevan A, Reddy CA. Ciezki JP, et al. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1347-50. doi: 10.1016/j.ijrobp.2004.05.067. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590163
Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study.
Elshaikh MA, Ulchaker JC, Reddy CA, Angermeier KW, Klein EA, Chehade N, Altman A, Ciezki JP. Elshaikh MA, et al. Among authors: ciezki jp. Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):164-9. doi: 10.1016/j.ijrobp.2004.09.036. Int J Radiat Oncol Biol Phys. 2005. PMID: 15850917 Clinical Trial.
Comparison of biochemical failure definitions for permanent prostate brachytherapy.
Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Kuban DA, et al. Among authors: ciezki jp. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1487-93. doi: 10.1016/j.ijrobp.2006.03.027. Epub 2006 Jun 5. Int J Radiat Oncol Biol Phys. 2006. PMID: 16750326
Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Zelefsky MJ, et al. Among authors: ciezki jp. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):327-33. doi: 10.1016/j.ijrobp.2006.08.056. Epub 2006 Nov 2. Int J Radiat Oncol Biol Phys. 2007. PMID: 17084558
111 results